
CASE REPORT FOR TWO SIBLINGS CARRYING
NEUROFIBROMATOSIS TYPE 1 WITH A RARE
NF1: c.5392C>T MUTATION Sayın Kocakap DB, Gündüz Ö, Özer L, Durak M *Corresponding Author: Associate Professor Derya B. Sayın Kocakap, Kırıkkale Üniversitesi Tıp
Fakültesi Tıbbi Genetik AD, Ankara Yolu 7.km, 71450, Kırıkkale, Turkey. Tel.: +90-318-357-3300/5784.
Fax: +90-318-225-2819. E-mail: dsayin@yahoo.com page: 99
|
MATERIALS AND METHODS
Case 1. A 21-year-old male patient presented to our
dermatology clinic due to presternal papulopustular eruption,
consistent with bacterial folliculitis. Dermatological examination revealed multiple café au lait macules along
with a few asymptomatic subcutaneous soft papules on
his shoulders and deltoid regions. Bilateral inguinal and
axillary freckling were also present (Figure 1). Lisch
nodules on both irides were seen in his ophthalmological
examination. Based upon the presence of axillary and inguinal freckling, café au lait macules, and Lisch nodules,
the patient was diagnosed with NF1. Further clinical
examination and anamnesis did not reveal any other sign
or symptom of NF1.
Case 2. After a few weeks, a 24-year-old female patient,
the elder sister of the first case, presented at our
clinic due to the recent diagnosis of her brother with NF1,
although she did not have any specific complaints. Several
asymptomatic light brown patches, café au lait spots,
were visible on her abdomen, in the right lower quadrant,
and on her right flank [Figure 2(a) and 2(b)]. The flexor
surfaces of her right arm and forearm were covered with
flesh-colored, painless non indurated continuous plaques [Figure 2(a)]. Her left arm was also hypertrichotic [Figure
2(c)]. A biopsy from the plaques revealed prominent immunohistochemical
staining with S100, indicating a neural
sheath tumor. Further opthalmological, neurological and
orthopedic examinations revealed no additional pathology.
The family medical history showed similar skin lesions in
their paternal grandfather, father, uncle, aunt, cousins and
brother. The pedigree is shown in Figure 3.
Mutation Analysis. Genomic DNA was isolated
from peripheral blood samples using the QIAamp DNA
Blood Mini kit (Qiagen GmbH, Hilden, Germany) according
to the manufacturer’s instructions. Next-generation
sequencing (NGS) was performed on a MiSeq
(Illumina Inc., San Diego, CA, USA), following the
manufacturer’s instructions for the NF1 gene. The procedure
for the preparation of libraries was performed
according to the manufacturer’s instructions. The hg19
(GRCh37) reference sequence was used as a reference
for identifying genetic variants. The variant call formats
(VCF) files were analyzed by Variant studio (Illumina
Inc.) and Geneticist Assistant (SoftGenetics, State College,
PA, USA) software program. The sensitivity of this
test was determined as 99.0% for 5.0% single nucleotide
polymorphism (SNP) allele fraction rate with 1000× coverage. The specificity of this test was determined
as 99.0% for 0.5% SNP allele fraction rate with 1000×
coverage. All identified variants are evaluated with respect
to their pathogenicity and causality and categorized
into classes according to the American College of
Medical Genetics and Genomics (ACMG) Standards and
Guidelines [6]. Heterozygous class 1 c.5392C>T, p.Gln
1798Ter mutation in exon 38 of the NF1 gene has been
detected with a mutation surveyor program. Detected variants were also analyzed and confirmed by Sanger
sequencing (Figure 4) according to the manufacturer’s
protocols. Briefly, the amplicons were analyzed by direct
sequencing with ABI PRISM® 3500 (Life Technologies,
Waltham, MA, USA). Analysis of sequence results was
done by the Mutation Surveyor program (SoftGenetics).
The primer sequences and polymerase chain reaction
(PCR) conditions will be provided by the corresponding
author upon request.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|